{"schema_version":"1.0","hypothesis_id":35476,"triple":{"drug":"ofatumumab","drug_canonical":"ofatumumab","mediator":"CD20","mediator_canonical":"cd20","outcome":"CDAI","outcome_canonical":"cdai"},"domain":{"domain":"cross_domain","source":"multiple_sclerosis","target":"rheumatoid_arthritis"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.2147/ceor.s503842","pmid":"40130187","year":2025,"roles":["drug_mediator"],"title":"Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model","journal":"Clinicoecon Outcomes Res","work_id":203099,"publication_date":"2025-03-01"},{"doi":"10.3389/fphar.2024.1521726","pmid":"39917326","year":2025,"roles":["drug_mediator"],"title":"Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis","journal":"Front Pharmacol","work_id":202770,"publication_date":"2025-01-23"},{"doi":"10.1159/000524946","pmid":"36160655","year":2022,"roles":["drug_mediator"],"title":"Immunocompetence after SARS-CoV-2 Infection in a Patient with Multiple Sclerosis Treated with Ofatumumab: A Case Report","journal":"Case Rep Neurol","work_id":212954,"publication_date":"2022-08-16"},{"doi":"10.1007/s40120-022-00401-4","pmid":"36048334","year":2022,"roles":["drug_mediator"],"title":"Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab","journal":"Neurol Ther","work_id":208137,"publication_date":"2022-09-01"},{"doi":"10.1080/1744666x.2022.2031982","pmid":"35107057","year":2022,"roles":["drug_mediator"],"title":"Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis","journal":"Expert Rev Clin Immunol","work_id":207086,"publication_date":"2022-02-01"},{"doi":"10.1007/s40263-021-00895-w","pmid":"35233753","year":2022,"roles":["drug_mediator"],"title":"Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis","journal":"CNS Drugs","work_id":199117,"publication_date":"2022-03-01"},{"doi":"10.1038/s41598-019-44895-9","pmid":"31186464","year":2019,"roles":["mediator_outcome"],"title":"General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis","journal":"Sci Rep","work_id":290504,"publication_date":"2019-06-11"}],"source_paper_count":7,"extracted_claims":[{"side":"drug_mediator","object":"CD20","context":"in relapsing multiple sclerosis patients","subject":"ofatumumab","work_id":199117,"claim_id":146120,"polarity":"positive","predicate":"binds_to","confidence":0.8,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"monoclonal antibody targeting CD20","subject":"ofatumumab","work_id":202770,"claim_id":151612,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"as a monoclonal antibody","subject":"ofatumumab","work_id":203099,"claim_id":152025,"polarity":"positive","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"multiple sclerosis treatment","subject":"ofatumumab","work_id":207086,"claim_id":157257,"polarity":"positive","predicate":"binds_to","confidence":0.8,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"","subject":"Ofatumumab","work_id":208137,"claim_id":158582,"polarity":"positive","predicate":"binds_to","confidence":1.0,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in relapsing multiple sclerosis","subject":"Ofatumumab","work_id":212954,"claim_id":163202,"polarity":"neutral","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"mediator_outcome","object":"CDAI","context":"in synovial tissue of patients with advanced stage rheumatoid arthritis","subject":"CD20","work_id":290504,"claim_id":222259,"polarity":"positive","predicate":"correlates_with","confidence":0.8,"extraction_run_id":29}],"extracted_claim_count":7,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[25,29]},"bridge":{"a_to_b_predicate":"binds_to","b_to_c_predicate":"correlates_with","a_to_b_evidence_count":6,"b_to_c_evidence_count":1,"edge_support_log_ab":1.9459101490553132,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.26390573296152586,"score":0.26390573296152586,"quality_tier":"mid","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}